东阳光药(01558.HK)拟7816万元收购东阳光生物制剂100%股权
格隆汇9月12日丨东阳光药(01558.HK)发布公告,2019年9月12日,本公司与深圳东阳光实业订立股权转让协议,据此,本公司同意收购东阳光生物制剂公司的全部股权,总代价7816万元人民币。
东阳光生物制剂公司为一家于2017年2月在中国注册成立的公司。其主要从事研发药品及医疗器械和生物技术研究。
公司称,公司为一家主要从事研发药品及医疗器械和生物技术研究的企业。本公司认为,收购事项将有利于本公司进一步扩大产能,为后续源源不断的储备产品的上市及销售打下坚实的基础。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.